• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

Five Challenges Filed Against Gilead Patent Claims For Hepatitis C Drug

20/05/2015 by Intellectual Property Watch Leave a Comment

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Pharmaceutical company Gilead Sciences has been noted first for developing an effective treatment for hepatitis C, which afflicts tens of millions around the world, and then offering it for jaw-dropping prices ($1000 per pill) in the United States and elsewhere. Now a group of health advocates has challenged Gilead’s patent applications in five emerging economies.

At issue is sofosbuvir, marketed under the brand name Sovaldi.

The group, led by the Initiative for Medicines, Access & Knowledge (I-MAK), filed the challenges in Argentina, Brazil, China, Russia and Ukraine. They argue that Gilead is abusing patent laws by claiming knowledge that is in the public domain as their own. More than 59 million people are living with hepatitis C across those five countries, and it affects some 150 million worldwide, the groups said.

I-MAK filed similar challenges in Europe last year with Medecins du Monde and in India with the Delhi Network of Positive People. These cases are still pending.

In a press release, the groups said it has been shown that a 12-week course of sofosbuvir could be produced by generic companies for as little as $101.

The World Health Organization this month added hepatitis C treatments, including sofosbuvir, to its list of essential medicines.

An analysis by Medecins Sans Frontieres (MSF, Doctor without Borders) showed that Gilead is expected to ask for between $2,000 and $15,000 for a 12-week sofosbuvir treatment in countries like Brazil, Argentina and China, the group said. People in those countries live on as little as $1.50 per day. Meanwhile, Gilead’s profits are soaring into the billions of dollars, said the advocates.

Gilead was not reached for this story.

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Creative Commons License"Five Challenges Filed Against Gilead Patent Claims For Hepatitis C Drug" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP-Watch Briefs, IP Policies, Language, Themes, Venues, Access to Knowledge/ Education, Asia/Pacific, English, Europe, Health & IP, Human Rights, IP Law, Innovation/ R&D, Latin America/Caribbean, Lobbying, North America, Patents/Designs/Trade Secrets, Regional Policy, Technical Cooperation/ Technology Transfer

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2021 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.